Insulet Corporation (NASDAQ: PODD) — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing does not provide a separate Q4 income statement. Insulet develops, manufactures and sells tubeless insulin-delivery systems, primarily the Omnipod platform, and supplies a modified Pod for Amgen’s Neulasta Onpro kit.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $1,697.1 million | $1,305.3 million |
| Gross profit / gross margin | $1,159.9 million / 68.3% | $805.6 million / 61.7% |
| Operating income | $220.0 million | $37.6 million |
| Net income | $206.3 million | $4.6 million |
| Diluted earnings per share | $2.94 | $0.07 |
| Cash provided by operating activities | $145.7 million | $119.0 million |
| Capital expenditures | $75.6 million | $122.9 million |
| Cash and cash equivalents at year-end | $704.2 million | $674.7 million |
| Total debt, net, at year-end | $1,415.8 million | $1,401.8 million |
Revenue grew 30.0% (29.6% on a constant-currency basis), driven mainly by Omnipod volume growth, customer additions and pharmacy-channel sales. U.S. Omnipod revenue rose 41.4% to $1,251.0 million; international Omnipod revenue rose 13.0% to $410.1 million. Drug Delivery revenue fell 37.4% to $36.0 million. The company reported one operating segment.
Gross margin improved by 6.6 percentage points. Management attributed much of the increase to the non-recurrence of a $57.9 million net charge for 2022 device corrections and an $11.5 million favorable revision to the correction liability in 2023; higher average selling prices and manufacturing efficiencies also helped. Operating cash flow included a $190.6 million working-capital cash outflow, principally from higher receivables, inventory and prepaid expenses. Cash less net debt was approximately negative $711.6 million; the filing reports a 33% net debt-to-total-capital ratio.
Material changes and unusual items
- Operating income increased to $220.0 million from $37.6 million, and net income rose to $206.3 million from $4.6 million. The comparison reflects strong sales growth and the prior-year device-correction charge, among other factors.
- Related-party revenue from a distributor was $473.7 million, up from $249.9 million, or about 28% of 2023 total revenue. The distributor is related through the spouse of a board member; the filing says the agreement’s terms are consistent with arm’s-length terms.
- Three distributors each represented at least 10% of revenue; together they accounted for 71% in 2023. The three also represented 78% of year-end trade receivables.
- Interest income increased to $28.6 million from $9.3 million, primarily due to higher interest rates. The effective tax rate was 3.9%, versus 53.4% in 2022, while a $202.9 million valuation allowance remained against net deferred tax assets.
- The company paid $25.1 million to acquire pump-based automated insulin-delivery patent assets. It also completed construction of its Malaysia manufacturing facility and expects production to begin in 2024.
Outlook, risks and contingencies
- For 2024, management expects strong U.S. Omnipod growth and higher international revenue, while noting that U.S. conversions to Omnipod 5 may be lower in the first half than in 2023. International growth is expected to face competition from other automated insulin-delivery systems.
- Management expects 2024 gross margin of 68%–69%; higher selling, general and administrative and research and development spending; higher capital expenditures; and Drug Delivery revenue to decline by $18–$22 million from 2023. It cites inflation, supply-chain costs, new product launches and Malaysia ramp-up among factors affecting costs.
- Product and market developments include FDA clearance of Omnipod GO in 2023, FDA clearance of the Omnipod 5 iPhone app in 2023 with a 2024 U.S. launch planned, and a pivotal type 2 diabetes trial for Omnipod 5. The company expected to complete the trial and submit an FDA application by the end of 2024.
- Supply risks include dependence on a China contract manufacturer, limited or sole-source components, semiconductor availability and the operational ramp-up of the Malaysia facility. The China manufacturing agreement expires in October 2025, subject to automatic renewal unless canceled under its terms.
- The company reported an adverse auditor opinion on internal control over financial reporting due to a material weakness in IT general controls supporting financial reporting outside North America. Management said remediation was underway; the weakness was not considered remediated at year-end. The auditor issued an unqualified opinion on the financial statements.
- The filing describes cybersecurity, privacy, reimbursement, regulatory, product-quality, competition, foreign-exchange and customer-retention risks. It disclosed a potential wireless vulnerability in Classic Omnipod associated with unauthorized DIY use; the company stated this practice does not exist with Omnipod 5. It also disclosed 2022 voluntary medical device corrections involving DASH PDM batteries and Omnipod 5 Controller charging components.
- The company had $800 million principal amount of 0.375% convertible notes due in September 2026, a $487.5 million term loan and a $300 million revolving credit facility with no amount outstanding at year-end. Management said liquidity should cover projected operating, investing and debt-service needs for at least 12 months. The credit agreement restricts certain transactions.
- The 2022 Roche patent litigation was settled for a one-time $20 million payment and a license. The filing says other ordinary-course proceedings are not expected to have a material adverse effect. The Amgen supply agreement for Neulasta Onpro runs to December 2028.
Key facts for investors to verify
- Progress, testing and remediation of the material weakness in financial-reporting IT controls, and whether controls become effective.
- Revenue quality and concentration: distributor dependence, the related-party distributor relationship, pharmacy-channel receivables and the estimation of rebates. Rebates charged against gross sales were $465.5 million in 2023.
- Whether 2024 revenue and margin expectations are achieved, including the effects of customer conversions, competition, product launches and the Malaysia manufacturing ramp.
- Debt repayment and refinancing capacity, the 2026 convertible-note maturity and the effect of potential conversion or dilution.
- Product correction costs, product safety and cybersecurity developments, and continued access to reimbursement and critical suppliers.